Geron Q4 net loss $42.6M; cash $173.1M; imetelstat NDA on track for mid-2023

GERON CORP

Net loss Q4 2022 $42.6M ($0.10/sh) vs $32.0M ($0.10) in Q4 2021; full year loss $141.9M ($0.37) vs $116.1M ($0.35).
Ended 2022 with $173.1M cash; subsequent raises added $273.1M net from Jan-Feb 2023 offering and warrant exercises.
2023 milestones: NDA submission mid-2023, MAA submission H2 2023; potential US launch H1 2024, EU launch end 2024.
2023 GAAP total expense guidance $210-220M; non-GAAP $200-210M; headcount to grow from 107 to 150-160 by year-end.
Positive IMerge Phase 3 top-line results reported Jan 2023; interim analysis from IMpactMF expected in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.